Modeling anti-HIV compounds: The role of analogue-based approaches

Current Computer-Aided Drug Design

Volumn 8, Issue 3, 2012, Pages 224-248

  Srivastava, Hemant Kumar ^a   Bohari, Mohammed H ^a   Sastry, G Narahari ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Analogue based approaches; Entry inhibitors; HIV and AIDS; Integrase inhibitors; Protease inhibitors; QSAR; Reverse transcriptase inhibitors

Indexed keywords

COMPUTATIONAL CHEMISTRY; DISEASES; METABOLISM; PYRIDINE; SCAFFOLDS; VIRUSES;

ANALOG-BASED APPROACH; ENTRY INHIBITOR; HIV AND AIDS; INTEGRASE; INTEGRASE INHIBITOR; PROTEASE INHIBITOR; QSAR; QSAR STUDIES; REVERSE TRANSCRIPTASE INHIBITOR; REVERSE-TRANSCRIPTASE;

UREA;

1 [(2 HYDROXYETHOXY)METHYL] 6 (PHENYLTHIO)THYMINE; 2 AMINO 6 ARYLSULFONYLBENZONITRILE; 2,3 DIARYL 1,3 THIAZOLIDIN 4 ONE; 3 AMINO 2 HYDROXYL 4 PHENYLBUTANOIC ACID; BENZONITRILE; BUTYRIC ACID; CARBOXYLIC ACID DERIVATIVE; DIARYLPYRIMIDINE; DIARYLTRIAZINE; DIHYDROALKOXYBENZYLOXOPYRIMIDINE; FULLERENE DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THIAZOLIDINE DERIVATIVE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; UREA DERIVATIVE;

BINDING AFFINITY; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; COMPUTER AIDED DESIGN; CRYSTAL STRUCTURE; DATA ANALYSIS; DRUG BINDING; DRUG CONFORMATION; DRUG DESIGN; DRUG STRUCTURE; HYDROGEN BOND; MOLECULAR DOCKING; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

EID: 84863973117     PISSN: 15734099     EISSN: 18756697     Source Type: Journal    
DOI: 10.2174/157340912801619085     Document Type: Review

References (233)

1. World AIDS Day report 2011: UNIAIDS (www.unaids.org).
2. Mitsuya, H.; Broder, S. Strategies for antiviral therapy of AIDS. Nature, 1987, 325, 773-778.
3. Flexner, C. HIV drug development: The next 25 years. Nat. Rev. Drug Discov., 2007, 6, 959-966.
4. Mehellou, Y.; Clercq, E.D. Twenty-six years of anti-HIV drug discovery: Where do we stand and where do we go? J. Med. Chem., 2010, 53, 521-538.
5. Mitsuya, H.; Weinhold, K.J.; Furman, P.A.S.; Clair, M.H.; Lehrman, S.N.; Gallo, R.C.; Bolognesi, D.; Barry, D.W.; Broder, S. 3α-Azido-3α-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human Tlymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA, 1985, 82, 7096-7100.
6. Flexner, C. HIV-protease inhibitors. N. Engl. J. Med., 1998, 338, 1281-1292.
7. Gulick, R.M. New antiretroviral drugs. Clin. Microbiol. Infect., 2003, 9, 186-193.
8. Burton, A. Enfuvirtide approved for defusing HIV. Lancet Infect. Dis., 2003, 3, 260.
9. Hicks, C.; Gulick, R.M. Raltegravir: The first HIV type 1 integrase inhibitor. Clin Infect Dis., 2009, 48, 931-939.
10. Reddy, A.S.; Pati, S.P.; Kumar, P.P.; Pradeep, H.N.; Sastry, G.N. Virtual screening in drug discovery-a computational perspective. Curr. Protein Pept. Sci., 2007, 8, 329-351.
11. Claus, B.L.; Underwood, D.J. Discovery informatics: Its evolving role in drug discovery. Drug Discov. Today, 2002, 7, 957-966.
12. Badrinarayan, P.; Sastry, G.N. Virtual high-throughput screening in new lead identification. Comb. Chem. High Thr. Screen., 2011, 14, 840-860.
13. Jorgensen, W.L. The many roles of computation in drug discovery. Science, 2004, 303, 1813-1818.
14. Bohari, M.H.; Srivastava H.K.; Sastry, G.N. Analogue based approaches in anticancer compound modelling: The relevance of QSAR models. Org. Med. Chem. Lett., 2011, 1, 3-15.
15. Srivani, P.; Sastry, G.N. Potential choline kinase inhibitors: a molecular modeling study of bis-quinolinium compounds. J. Mol. Graph. Model., 2009, 27, 676-688.
16. Kumar, S.H. A comparative QSPR study of alkanes with the help of computational chemistry. Bull. Kor. Chem. Soc., 2009, 30, 67-76.
17. Janardhan, S.; Srivani, P.; Sastry, G.N. 2D and 3D quantitative structure-activity relationship studies on a series of bis-pyridinium compounds as choline kinase inhibitors. QSAR Combi Sci, 2006, 25, 860-872
18. Ravindra, G.K.; Achaiah, G.; Sastry, G.N. Molecular modeling studies of phenoxy-pyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking. Eur. J. Med. Chem., 2008, 43, 830-838.
19. Srivastava, H.K.; Pasha, F.A.; Singh, P.P. Atomic softness-based QSAR study of testosterone. Int. J. Quant. Chem., 2005, 103, 237-245.
20. Roy, D.R.; Parthasarathi, R.; Maiti, B.; Subramanianb, V.; Chattaraj, P.K. Electrophilicity as a possible descriptor for toxicity prediction. Bioorg. Med. Chem., 2005, 13, 3405-3412.
21. Reddy, A.S.; Jallahalli, V.; Garg, R.; Zhang, X.; Sastry, G.N.; Kumar, S. Analysis of HIV protease binding pockets based on 3D shape and electrostatic potential descriptors. Chem. Biol. Drug. Des., 2011, 77, 137-151.
22. Srivastava, H.K.; Chourasia, M.; Kumar, D.; Sastry, G.N. Comparison of computational methods to model DNA minor groove binders. J. Chem. Inf. Model., 2011, 51, 558-571.
23. Parthasarathi, R.; Subramanian, V.; Roy, D.R.; Chattaraj, P.K. Electrophilicity index as a possible descriptor of biological activity. Bioorg. Med. Chem., 2004, 12, 5533-5543.
24. Janardhan, S.; Srivani, P.; Sastry, G.N. Choline kinase: an important target for cancer. Curr. Med. Chem., 2006, 13, 1169-1186.
25. Srivastava, H.K.; Pasha, F.A.; Mishra, S.K.; Singh, P.P. Novel applications of atomic softness and QSAR study of testosterone derivatives. Med. Chem. Res., 2009, 18, 455-466.
26. Srivani, P.; Sastry, G.N. Potential choline kinase inhibitors: A molecular modeling study of bis-quinolinium compounds. J. Mol. Graph. Mod., 2009, 27, 676-688.
27. Srivastava, H.K.; Choudhury, C.; Sastry, G.N. The efficacy of conceptual DFT descriptors and docking scores on the QSAR models of HIV protease inhibitors. Med. Chem., 2012, Accepted.
28. Badrinarayan, P.; Srivani, P.; Sastry, G.N. Design of 1-arylsulfamido-2-alkylpiperazine derivatives as secreted PLA2 inhibitors. J. Mol. Model., 2011, 17, 817-831.
29. Pasha, F.A.; Muddassar, M.; Beg, Y.; Cho, S.J. DFT-based de novo QSAR of phenoloxidase inhibitors. Chem. Biol. Drug. Des., 2008, 71, 483-493.
30. Ravindra, G.K.; Srivani, P.; Achaiah, G.; Sastry, G.N. Strategies to design pyrazolyl urea derivatives for p38 kinase inhibition: a molecular modeling study. J. Comput.-Aided Mol. Des., 2007, 25, 155-166.
31. Miyasaka, T.; Tanaka, H.; Baba, M.; Hayakawa, H.; Walker, R.T.; Balzarini, J.; DeClercq, E. A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio) thymine. J. Med. Chem., 1989, 32, 2507-2509.
32. Hannongbua, S.; Lawtrakul, L.; Limtrakul, J. Structure-activity correlation study of HIV-1 inhibitors: Electronic and molecular parameters. J. Comput.-Aided Mol. Des., 1996, 10, 145-152.
33. Hannongbua, S.; Lawtrakul, L.; Sotriffer, C.A.; Rode, B.M. Comparative molecular field analysis of HIV-1 reverse transcriptase inhibitors in the class of 1-[(2-Hydroxyethoxy)-ethyl]-6-(phenylthio)thymine. Quant. Struct.-Act. Relat., 1996, 15, 389-394.
34. Kireev, D.B.; Chretien, J.R.; Grierson, D.S.; Monneret, C. A 3D QSAR study of a series of HEPT analogues: The influence of conformational mobility on HIV-1 reverse transcriptase inhibition. J. Med. Chem., 1997, 40, 4257-4264.
35. Luco, J.M.; Ferretti, F.H. QSAR based on multiple linear regression and PLS methods for the anti-HIV activity of a large group of HEPT derivatives. J. Chem. Inf. Comput. Sci., 1997, 37, 392-401.
36. Tronchet, J.M.J.; Grigorov, M.; Dolatshahi, N.; Moriaud, F.; Weber, J. A QSAR study confirming the heterogeneity of the HEPT derivative series regarding their interaction with HIV reverse transcriptase. Eur. J. Med. Chem., 1997, 32, 279-299.
37. Lawtrakul, L.; Hannongbua, S. Quantitative structure-activity relationships of HIV-1 RT inhibitors in the class of 1-[(2-Hydroxyethoxy) methyl]-5,6-substituted thymine [HEPT] analogues. Sci. Pharm., 1999, 67, 43-56.
38. Jalali-Heravi, M.; Parastar, F. Use of artificial neural networks in a QSAR study of anti-HIV activity for a large group of HEPT derivatives. J. Chem. Inf. Comput. Sci., 2000, 40, 147-154.
39. Klein, C.T.; Lawtrakul, L.; Hannongbua, S.; Wolschann, P. Accessible charges in structure activity relationships. A study on HEPT-based HIV-1 RT inhibitors. Sci. Pharm., 2000, 68, 25-40.
40. Garg, R.; Gupta, S.P.; Gao, H.; Babu, M.S.; Debnath, A. K; Hansch, C. Comparative quantitative structure activity relationship studies on anti-HIV drugs. Chem. Rev., 1999, 99, 3525-3601.
41. Gaudio, A.C.; Montanari, C.A. HEPT derivatives as nonnucleoside inhibitors of HIV-1 reverse transcriptase: QSAR studies agree with the crystal structures. J. Comput.-Aided Mol. Des., 2002, 16, 287-295.
42. Hannongbua, S.; Nivesanond, K.; Lawtrakul, L.; Pungpo, P. 3D quantitative structure-activity relationships of HEPT derivatives as HIV-1 reverse transcriptase inhibitors, based on ab initio calculations. J. Chem. Inf. Comput. Sci., 2001, 41, 848-855.
43. Pungpo, P.; Hannongbua, S.; Wolschann, P. Hologram quantitative structure-activity relationships investigations of non-nucleoside reverse transcriptase inhibitors. Curr. Med. Chem., 2003, 10, 1661-1677.
44. Douali, L.; Villemin, D.; Cherqaoui, D. Neural networks: Accurate nonlinear QSAR model for HEPT derivatives. J. Chem. Inf. Comput. Sci., 2003, 43, 1200-1207.
45. Douali, L.; Villemin, D.; Cherqaoui, D. Comparative QSAR based on neural networks for the anti-HIV activity of HEPT derivatives. Curr. Pharm. Des., 2003, 9, 1817-26.
46. Gayen, S.; Debnath, B.; Samanta, S.; Jha, T. QSAR study on some anti-HIV HEPT analogues using physicochemical and topological parameters. Bioorg. Med. Chem., 2004, 12, 1493-1503.
47. Polanski, J.; Gieleciak, R.; Magdziarz, T.; Bak, A. GRID formalism for the comparative molecular surface analysis: Application to the CoMFA benchmark steroids, azo dyes, and HEPT derivatives. J. Chem. Inf. Comput. Sci., 2004, 44, 1423-1435.
48. Bak, A.; Polanski, J. A 4D-QSAR study on anti-HIV HEPT analogues. Bioorg. Med. Chem., 2006, 14, 273-279.
49. Kompany-Zareh, M.; Akhlaghi, Y. Correlation weighted successive projections algorithm as a novel method for variable selection in QSAR studies: Investigation of anti-HIV activity of HEPT derivatives. J. Chemometr., 2007, 21, 239-250.
50. Riahi, S.; Pourbasheer, E.; Dinarvand, R.; Ganjali, M.R. Norouzi, P. Quantitative structure-activity relationship study on the anti-HIV-1 activity of novel 6-Naphthylthio HEPT analogs. Chem. Biol. Drug Des., 2009, 74, 165-172.
51. Pauwels, R.; Andries, K.; Desmyter, J.; Schols, D.; Kukla, M.J.; Breslin, H.J.; Raeymaechers, A.; Gelder, J.V.; Woestenborgs, R.; Heykants, J.; Schellekens, K.; Janessen, M.A.C.; De Clercq, E.; Janssen, P.A.J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature, 1990, 343, 470-474.
52. Gupta, S.P.; Garg, R. Quantitative structure-activity relationship studies on anti-HIV-1 TIBO derivatives as inhibitors of viral reverse transcriptase. J. Enzym. Inhib. Med. Chem., 1996, 11, 23-32.
53. Hannongbua, S.; Pungpo, P.; Limtrakul, J.; Wolschann, P. Quantitative structure-activity relationships and comparative molecular field analysis of TIBO derivatised HIV-1 reverse transcriptase inhibitors. J. Comput.-Aided Mol. Des., 1999, 13, 563-577.
54. Barreca, M.L.; Carotti, A.; Carrieri, A.; Chimirri, A.; Monforte, A.M.; Calace, M.P.; Rao, A. Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs). Bioorg. Med. Chem., 1999, 7, 2283-2292.
55. Huuskonen, J. QSAR modeling with the electrotopological state: TIBO derivatives. J. Chem. Inf. Comput. Sci., 2001, 41, 425-429.
56. Sapre, N.S.; Pancholi, N.; Gupta, S.; Sapre, N. Computational modeling of tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone derivatives: An atomistic drug design approach using Kier-Hall electrotopological state (E-State) indices. J. Comput. Chem., 2008, 29, 1699-1706.
57. Sapre, N.S.; Pancholi, N.; Gupta, S.; Sapre, N. A group center overlap based approach for "3D QSAR" studies on TIBO derivatives. J. Comput. Chem., 2009, 30, 922-933.
58. Darnag, R.; Mazouz, E.L.M.; Schmitzer, A.; Villemin, D.; Jarid, A.; Cherqaoui, D. Support vector machines: Development of QSAR models for predicting anti-HIV-1 activity of TIBO derivatives. Eur. J. Med. Chem., 2010, 45, 1590-1597.
59. Zhou, Z.; Madura, J.D. CoMFA 3D-QSAR analysis of HIV-1 RT nonnucleoside inhibitors, TIBO derivatives based on docking conformation and alignment. J. Chem. Inf. Comput. Sci., 2004, 44, 2167-2178.
60. Zhang, Z.; Zheng, M.; Du, L.; Shen, J.; Luo, X.; Zhu, W.; Jiang, H. Towards discovering dual functional inhibitors against both wild type and K103N mutant HIV-1 reverse transcriptases: Molecular docking and QSAR studies on 4,1-benzoxazepinone analogues. J. Comput. Aided Mol. Des., 2006, 20, 281-293.
61. Mandal, A.S.; Roy, K. Predictive QSAR modeling of HIV reverse transcriptase inhibitor TIBO derivatives. Eur. J. Med. Chem., 2009, 44, 1509-1524.
62. Goodarzi, M.; Freitas, M.P. MIA-QSAR coupled to principal component analysis-adaptive neuro-fuzzy inference systems (PCA-ANFIS) for the modeling of the anti-HIV reverse transcriptase activities of TIBO derivatives. Eur. J. Med. Chem., 2010, 45, 1352-1358.
63. De Clercq, E. HIV-chemotherapy and-prophylaxis: New drugs, leads and approaches. Int. J. Biochem. Cell Biol., 2004, 36, 1800-1822.
64. De Clercq, E. New approaches toward anti-HIV chemotherapy. J. Med. Chem., 2005, 48, 1297-1313.
65. Araujo de Brito, M.; Rodrigues, C.R.; Cirino, J.J.V.; Bicca de Alencastro, R.; Castro, H.C.; Albuquerque, M.G. 3D-QSAR CoMFA of a series of DABO derivatives as HIV-1 reverse transcriptase non-nucleoside inhibitors. J. Chem. Inf. Model., 2008, 48, 1706-1715.
66. Ludovici, D.W.; De Corte, B.L.; Kukla, M.J.; Ye, H.; Ho, C.Y.; Lichtenstein, M.A.; Kavash, R.W.; Andries, K.; de Bethune, M.-P.; Azijn, H.; Pauwels, R.; Lewi, P.J.; Heeres, J.; Koymans, L.M.H.; de Jonge, M.R.; Van Aken, K.J.A.; Daeyaert, F.F.D.; Das, K.; Arnold, E.; Janssen, P.A.J. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorg. Med. Chem. Lett., 2001, 11, 2235-2239.
67. Thakur, A.; Thakur, M.; Bharadwaj, A.; Thakur, S. SAR and QSAR studies: Modelling of new DAPY derivatives. Eur. J. Med. Chem., 2008, 43, 471-477.
68. Rebehmed, J.; Barbault, F.; Teixeira, C.; Maurel, F. 2D and 3D QSAR studies of diarylpyrimidine HIV-1 reverse transcriptase inhibitors. J. Comput.-Aided Mol. Des., 2008, 22, 831-841.
69. Park, H.Y.; Ju, S.M.; Lee, D.Y.; Zhang, H.; Kim, C.K. 3D-QSAR studies on DATAs and DAPYs for HIV-RT inhibitors using CoMFA and CoMSIA approaches. QSAR Comb. Sci., 2009, 28, 218-225.
70. Li, Z.; Han, J.; Chen, H.F. Revealing interaction mode between HIV-1 reverse transcriptase and diaryltriazine analog inhibitor. Chem. Biol. Drug Des., 2008, 72, 350-359.
71. Li, Z.; Zhang, H.; Li, Y.; Zhang, J.; Chen, H.-F. Drug resistant mechanism of diaryltriazine analog inhibitors of HIV-1 reverse transcriptase using molecular dynamics simulation and 3D-QSAR. Chem. Biol. Drug Des., 2011, 77, 63-74.
72. Medina-Franco, J.L.; Rodrguez-Morales, S.; Juarez-Gordiano, C.; Hernandez-Campos, A.; Castillo, R. Docking-based CoMFA and CoMSIA studies of non-nucleoside reverse transcriptase inhibitors of the pyridinone derivative type. J. Comput.-Aided Mol. Des., 2004, 18, 345-360.
73. Dureja, H.; Madan, A.K. Predicting anti-HIV activity of dimethylaminopyridin-2-ones: Computational approach using topochemical descriptors. Chem. Biol. Drug Des., 2009, 73, 258-270.
74. Medina-Franco, J.L.; Golbraikh, A.; Oloff, S.; Castillo, R.; Tropsha, A. Quantitative structure-activity relationship analysis of pyridinone HIV-1 reverse transcriptase inhibitors using the k nearest neighbor method and QSAR-based database mining. J. Comput.-Aided Mol. Des., 2005, 19, 229-242.
75. Chan, J.H.; Hong, J.S.; Hunter III, R.N.; Orr, G.F.; Cowan, J.R.; Sherman, D.B.; Sparks, S.M.; Reitter, B.E.; Andrews III, C.W.; Hazen, R.J.; St Clair, M.; Boone, L.R.; Ferris, R.G.; Creech, K.L.; Roberts, G.B.; Short, S.A.; Weaver, K.; Ott, R.J.; Ren, J.; Hopkins, A.; Stuart, D.I.; Stammers, D.K. 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J. Med. Chem., 2001, 44, 1866-1882.
76. Leonard, J.T.; Roy, K. Classical QSAR modeling of HIV-1 reverse transcriptase inhibitor 2-amino-6-arylsulfonylbenzonitriles and congeners. QSAR Comb. Sci., 2004, 23, 23-35.
77. Roy, K.; Leonard, J.T. QSAR modeling of HIV-1 reverse transcriptase inhibitor 2-amino-6-arylsulfonylbenzonitriles and congeners using molecular connectivity and E-state parameters. Bioorg. Med. Chem., 2004, 12, 745-754.
78. Sciabola, S.; Carosati, E.; Baroni, M.; Mannhold, R. Comparison of ligand-based and structure-based 3D-QSAR approaches: a case study on (aryl-) bridged 2-aminobenzonitriles inhibiting HIV-1 reverse transcriptase. J. Med. Chem., 2005, 48, 3756-3767.
79. Pastor, M.; Cruciani, G.; McLay, I.; Pickett, S.; Clementi, S. GRid-INdependent Descriptors (GRIND): a novel class of alignmentindependent three-dimensional molecular descriptors. J. Med. Chem., 2000, 43, 3233-3243.
80. Hemmateenejad, B.; Sabet, R.; Fassihi, A. Quantitative structure-activity relationship studies on 2-amino-6-arylsulfonylbenzonitriles as human immunodeficiency viruses type 1 reverse transcriptase inhibitors using descriptors obtained from substituents and whole molecular structures. Chem. Biol. Drug Des., 2009, 74, 405-415.
81. Hu, R.; Doucet, J.-P.; Delamar, M.; Zhang, R. QSAR models for 2-amino-6-arylsulfonylbenzonitriles and congeners HIV-1 reverse transcriptase inhibitors based on linear and nonlinear regression methods. Eur. J. Med. Chem., 2009, 44, 2158-2171.
82. Chimirri, A.; Grasso, S.; Molica, C.; Monforte, A.M.; Monforte, P.; Zappala, M.; Bruno, G.; Niclo, F.; Witvrouw, M.; Jonckeere, H.; Balzarini, J.; De Clercq, E. Structural features and anti-HIV activity of the isomers of 1-(2',6'-difluorophenyl)-1H,3Hthiazolo[3,4-a]benzimidazole, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Antiviral Chem. Chemother., 1997, 8, 363-370.
83. Chimirri, A.; Grasso, S.; Monforte, A.M.; Monforte, P.; Rao, A.M.; Zappala, M.; Bruno, G.; Niclo, F.; Witvrouw, M.; Pannecouque, C.; Balzarini, J.; De Clercq, E. Synthesis and biological activity of novel 1H,3H-thiazolo[3,4-a]benzimidazoles: Non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors. Antiviral Chem. Chemother., 1999, 10, 211-217.
84. Barreca, M.L.; Chimirri, A.; Carotti, A.; Monforte, A.M.; Monforte, P.; Calace, M.P.; Rao, A. Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs). Bioorg. Med. Chem., 1999, 7, 2283-2292.
85. Barreca, M.L.; Chimirri, A.; De Luca, L.; Monforte, A.M.; Monforte, P.; Calace, M.P.; Rao, A.; Zappala, M.; Balzarini, J.; De Clercq, E. Pannecouque, C.; Witvrouw, M. Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. Bioorg. Med. Chem. Lett., 2001, 11, 1793-1796.
86. Barreca, M.L.; Balzarini, J.; Chimirri, A.; De Clercq, E.; De Luca, L.; Holtje, H.D.; Holtje M.; Monforte, A.M.; Monforte, P.; Pannecouqe, C.; Rao, A.; Zapalla, M. Design, synthesis, structure activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents. J. Med. Chem., 2002, 45, 5410-5413.
87. Prabhakar, Y.S.; Solomon, V.R.; Rawal, R.K.; Gupta, M.K.; Katti, S.B. CP-MLR/PLS directed structure-activity modeling of the HIV-1 RT inhibitory activity of 2,3-diaryl-1,3-thiazolidin-4-ones. QSAR Comb. Sci., 2004, 23, 234-244.
88. Ravichandran, V.; Kumar, B.R.P.; Sankar, S.; Agrawal, R.K. Predicting anti-HIV activity of 1,3,4-thiazolidinone derivatives: 3D-QSAR approach. Eur. J. Med. Chem., 2009, 44, 1180-1187.
89. Lam, P.Y.; Jadhav, P.K.; Eyermann, C.J.; Hodge, C.N.; Ru, Y.; Bacheler, L.T.; Meek, J.L.; Otto, M.J.; Rayner, M.M.; Wong, Y.N.; Chang, C.H.; Wever, P.C.; Jackson, D.A.; Sharpe, T.R.; Erickson-Vittanen, S. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science, 1994, 263, 380-384.
90. Gayathri, P.; Pande, V.; Sivakumar, R.; Gupta, S.P. A quantitative structure-activity relationship study on some HIV-1 protease inhibitors using molecular connectivity index. Bioorg. Med. Chem., 2001, 9, 3059-3063.
91. Katritzky, A.R.; Oliferenko, A.; Lomaka, A.; Karelson, M. Sixmembered cyclic ureas as HIV-1 protease inhibitors: A QSAR study based on CODESSA PRO approach. Bioorg. Med. Chem. Lett., 2002, 12, 3453-3457.
92. Milac, A.-L.; Avram, S.; Petrescu, A.-J. Evaluation of a neural networks QSAR method based on ligand representation using substituent descriptors: Application to HIV-1 protease inhibitors. J. Mol. Graph. Model., 2006, 25, 37-45.
93. Avram, S.; Bologa, C.; Flonta, M.-L. Quantitative structure-activity relationship by CoMFA for cyclic urea and nonpeptide-cyclic cyanoguanidine derivatives on wild type and mutant HIV-1 protease. J. Mol. Model., 2005, 11, 105-115.
94. Garg, R.; Bhhatarai, B. A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR. Bioorg. Med. Chem., 2004, 12, 5819-5831.
95. Garg, R.; Patel, D. Hydrophobicity in the design of P2/P2β tetrahydropyrimidinone HIV protease inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 3767-3770.
96. Khedkar, V.M.; Ambre, P.K.; Verma, J.; Shaikh, M.S.; Pissurlenkar, R.R.S.; Coutinho, E.C. Molecular docking and 3D QSAR studies of HIV-1 protease inhibitors. J. Mol. Model., 2010, 16, 1251-1268.
97. Sivan, S.K.; Manga, V. Multiple receptor conformation docking and dock pose clustering as tool for CoMFA and CoMSIA analysis-A case study on HIV-1 protease inhibitors. J. Mol. Model., 2011, 18, 569-82.
98. Nair, A.C.; Jayatilleke, P.; Wang, X.; Miertus, S.; Welsh, W.J. Computational studies on tetrahydropyrimidine-2-one HIV-1 protease inhibitors: Improving three-dimensional quantitative structure-activity relationship comparative molecular field analysis models by inclusion of calculated inhibitor-and receptor-based properties. J. Med. Chem., 2002, 45, 973-983.
99. Friedman, H.S.; DeCamp, D.L.; Sijbesma, R.P.; Srdanov, G.; Wudl, F.; Kenyon, G. Inhibition of the HIV-1 protease by fullerene derivatives: Model building studies and experimental verification. J. Am. Chem. Soc., 1993, 115, 6506.
100. Friedman, H.S.; Ganapathi, P.S.; Rubin, P.S.; Kenyon, G.L. Optimizing the binding of fullerene inhibitors of the HIV-1 protease through predicted increases in hydrophobic desolvation. J. Med. Chem., 1998, 41, 2424.
101. Durdagi, S.; Mavromoustakos, T.; Papadopoulos, M.G. 3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 6283-6289.
102. Durdagi, S.; Mavromoustakos, T.; Chronakis, N.; Papadopoulos, M.G. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations. Bioorg. Med. Chem., 2008, 16, 9957-9974.
103. Toropov, A.A.; Toropova, A.P.; Benfenati, E.; Leszczynska, D.; Leszczynski, J. SMILES-based optimal descriptors: QSAR analysis of fullerene-based HIV-1 PR inhibitors by means of balance of correlations. J. Comput. Chem., 2010, 31, 381-392.
104. Doweyko, A.M. QSAR: Dead or alive? J. Comput.-Aided Mol. Des., 2008, 22, 81-89.
105. Johnson, R.S. The trouble with QSAR (or how i learned to stop worrying and embrace fallacy). J. Chem. Inf. Model., 2008, 48, 25-26.
106. Golbraikh, A.; Tropsha, A. Beware of q2! J. Mol. Graph. Model., 2002, 20, 269-276.
107. Roy, P.P.; Roy, K. On some aspects of variable selection for partial least squares regression models. QSAR Comb. Sci., 2008, 27, 302-313.
108. Toropov, A.A.; Leszczynski, J. A new approach to the characterization of nanomaterials: Predicting Young's modulus by correlation weighting of nanomaterials codes. Chem. Phys. Lett., 2006, 433, 125-129.
109. Toropov, A.A.; Toropova, A.P.; Benfenati, E.; Leszczynska, D.; Leszczynski, J. InChI-based optimal descriptors: QSAR analysis of fullerene[C60]-based HIV-1 PR inhibitors by correlation balance. Eur. J. Med. Chem., 2010, 45, 1387-1394.
110. Sakurai, M.; Higashida, S.; Sugano, M.; Komai, T.; Yagi, R.; Ozawa, Y.; Handa, H.; Nishigaki, T.; Yabe, Y. Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA. Bioorg. Med. Chem., 1994, 2, 807-825.
111. Komai, T.; Higashida, S.; Sakurai, M.; Nitta, T.; Kasuya, A.; Miyamaoto, S.; Yagi, R.; Ozawa, Y.; Handa, H.; Mohri, H.; Yasuoka, A.; Oka, S.; Nishigaki, T.; Kimura, S.; Shimada, K.; Yabe, Y. Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA?II. Modification of pyrrolidine ring at P1 proline. Bioorg. Med. Chem., 1996, 4, 1365-1377.
112. Takashiro, E.; Watanabe, T.; Nitta, T.; Kasuya, A.; Miyamoto, S.; Ozawa, Y.; Yagi, R.; Nishigaki, T.; Shibayama, T.; Nakagawa, A.; Iwamoto, A.; Yabe, Y. Structure-activity relationship of HIV-1 protease inhibitors containing AHPBA. Part III: Modification of P2 site. Bioorg. Med. Chem., 1998, 6, 595-604.
113. Takashiro, E.; Hayakawa, I.; Nitta, T.; Kasuya, A.; Miyamoto, S.; Ozawa, Y.; Yagi, R.; Yamamoto, I.; Shibayama, T.; Nakagawa, A.; Yabe, Y. Structure-activity relationship of HIV-1 protease inhibitors containing R-hydroxy-â-amino acids. Detailed study of P1 site. Bioorg. Med. Chem., 1999, 7, 2063-2072.
114. Huang, X.; Xu, L.; Luo, X.; Fan, K.; Ji, R.; Pei, G.; Chen, K.; Jiang, H. Elucidating the inhibiting mode of AHPBA derivatives against HIV-1 protease and building predictive 3D-QSAR models. J. Med. Chem., 2002, 45, 333-343.
115. Senese, C.L.; Hopfinger, A.J. Receptor-independent 4D-QSAR analysis of a set of norstatine derived inhibitors of HIV-1 protease. J. Chem. Inf. Comput. Sci., 2003, 43, 1297-1307.
116. Meek, T.D. Inhibitors of HIV-1 protease. J. Enzyme Inhib., 1992, 6, 65-98.
117. Thaisrivongs, S. HIV protease inhibitors. Annu. Rep. Med. Chem., 1994, 17, 133-144.
118. Moyle, G.; Gazzard, B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs, 1996, 5, 701-712.
119. Tait, B.D.; Hagen, S.; Domagala, J.; Ellsworth, E.L.; Gajda, C.; Hamilton, H.W.; Vara Prasad, J.V.N.; Ferguson, D.; Graham, N.; Hupe, D.; Nouhan, C.; Tummino, P.J.; Humblet, C.; Lunney, E.A.; Pavlovsky, A.; Rubin, J.; Gracheck, S.J.; Baldwin, E.T.; Bhat, T.N.; Erickson, J.W.; Gulnik, S.V.; Liu, B. 4-Hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease. J. Med. Chem., 1997, 40, 3781-3792.
120. Bhhatarai, B.; Garg, R. From SAR to comparative QSAR: Role of hydrophobicity in the design of 4-hydroxy-5,6-dihydropyran-2-ones HIV-1 protease inhibitors. Bioorg. Med. Chem., 2005, 13, 4078-4084.
121. Santos-Filho, O.A.; Hopfinger, A.J. Structure-based QSAR analysis of a set of 4-hydroxy-5,6-dihydropyrones as inhibitors of HIV-1 protease: An application of the receptor-dependent (RD) 4D-QSAR formalism. J. Chem. Inf. Model., 2006, 46, 345-354.
122. Santos-Filho, O.A.; Hopfinger, A.J. The 4D-QSAR paradigm: Application to a novel set of nonpeptidic HIV protease inhibitors. Quant. Struct.-Act. Relat., 2002, 21, 369-381.
123. Prasad, J.V.; Boyer, F.E.; Domagala, J.M.; Ellsworth, E.L.; Gajda, C.; Hamilton, H.W.; Hagen, S.E.; Markoski, L.J.; Steinbaugh, B.A.; Tait, B.D.; Humblet, C.; Lunney, E.A.; Pavlovsky, A.; Rubin, J.R.; Ferguson, D.; Graham, N.; Holler, T.; Hupe, D.; Nouhan, C.; Tummino, P.J.; Uromov, A.; Zeikus, E.; Zeikus, G.; Gracheck, S.J.; Saunders, J.M.; VanderRoest, S.; Brodfuehrer, J.; Iyer, K.; Sinz, M.; Gulnik, S.V.; Erickson, J.W. Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: A lead HIV protease inhibitor. Bioorg. Med. Chem., 1999, 7, 2775-2800.
124. Eich, E.; Pertz, H.; Kaloga, M.; Schulz, J.; Fesen, M.R.; Mazumder, A.; Pommier, Y. (-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virus type-1 integrase. J. Med. Chem., 1996, 39, 86-95.
125. Mazumder, A.; Raghavan, K.; Weinstein, J.; Kohn, K.W.; Pommier, Y. Inhibition of human immunodeficiency virus type-1 integrase by curcumin. Biochem. Pharmacol., 1995, 49, 1165-1170.
126. Cushman, M.; Sherman, P. Inhibition of HIV-1 integration protein by aurintricarboxylic acid monomers, monomer analogues, and polymer fractions. Biochem. Biophys. Res. Commun., 1992, 185, 85-90.
127. Robinson Jr., W.E.; Cordeiro, M.; Abdel-Malek, S.; Jia, Q.; Chow, S.A.; Reinecke, M.G.; Mitchell, W.M. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: Inhibition of the core catalytic domain of human immunodeficiency virus integrase. Mol. Pharmacol., 1996, 50, 846-855.
128. Robinson Jr., W.E.; Reinecke, M.G.; Abdel-Malek, S.; Jia, Q.; Chow, S.A. Inhibitors of HIV-1 replication that inhibit HIV integrase. Proc. Natl. Acad. Sci. USA, 1996, 93, 6326-6331.
129. Neamati, N.; Mazumder, A.; Zhao, H.; Sunder, S.; Burke Jr,. T.R.; Schultz, R.J.; Pommier, Y. Diaryl sulfones, a novel class of human immunodeficiency virus type 1 integrase inhibitors. Antimicrob. Agents Chemother., 1997, 41, 385-393.
130. Mazumder, A.; Neamati, N.; Sommadossi, J.-P.; Gosselin, G.; Schinazi, R.F.; Imbach, J.-L.; Pommier, Y. Effects of nucleotide analogues on human immunodeficiency virus type 1 integrase. Mol. Pharmacol., 1996, 49, 621-628.
131. Thomas, M.; Brady, L. HIV integrase: A target for AIDS therapeutics. TIBTECH, 1997, 15, 167-172.
132. Sato, M.; Kawakami, H.; Motomura, T.; Aramaki, H.; Matsuda, T.; Yamashita, M.; Ito, Y.; Matsuzaki, Y.; Yamataka, K.; Ikeda, S.; Shinkai, H. Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors. J. Med. Chem., 2009, 52, 4869-4882.
133. Leonard, J.T.; Roy, K. Exploring molecular shape analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors. Eur. J. Med. Chem., 2008, 43, 81-92.
134. Toropova, A.P.; Toropov, A.A.; Benfenati, E.; Gini, G. Simplified molecular input-line entry system and international chemical identifier in the QSAR analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors. Chem. Biol. Drug Des., 2011, 77, 343-360.
135. Lu, P.; Wei, X.; Zhang, R. CoMFA and CoMSIA 3D-QSAR studies on quionolone caroxylic acid derivatives inhibitors of HIV-1 integrase. Eur. J. Med. Chem., 2010, 45, 3413-3419.
136. Pommier, Y.; Johnson, A.A.; Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov., 2005, 4, 236-248.
137. Grobler, J.A.; Stillmock, K.; Binghua, H.; Witmer, M.; Felock, P.; Espeseth, A.S.; Wolfe, A.; Egbertson, M.; Bourgeois, M.; Melamed, J.; Wai, J.S.; Young, S.; Vacca, J.; Hazuda, D.J. Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes Proc. Natl. Acad. Sci. USA, 2002, 99, 6661-6666.
138. Hazuda, D.J.; Anthony, N.J.; Gomez, R.P.; Jolly, S.M.; Wai, J.S.; Zhuang, L.; Fisher, T.E.; Embrey, M.; Guare Jr., J.P.; Egbertson, M.S.; Vacca, J.P.; Huff, J.R.; Felock, P.J.; Witmer, M.V.; Stillmock, K.A.; Danovich, R.; Grobler, J.; Miller, M.D.; Espeseth, A.S.; Jin, L.; Chen, I.W.; Lin, J.H.; Kassahun, K.; Ellis, J.D.; Wong, B.K.; Xu, W.; Pearson, P.G.; Schleif, W.A.; Cortese, R.; Emini, E.; Summa, V.; Holloway, M.K.; Young, S.D. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl. Acad. Sci. USA, 2004, 101, 11233-11238.
139. Cheng, Z.; Zhang, Y.; Fu, W. QSAR study of carboxylic acid derivatives as HIV-1 Integrase inhibitors. Eur. J. Med. Chem., 2010, 45, 3970-3980.
140. Sharma, H.; Patil, S.; Sanchez, T.W.; Neamati, N.; Schinazi, R.F.; Buolamwini, J.K. Synthesis, biological evaluation and 3D-QSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1 integrase inhibitors. Bioorg. Med. Chem., 2011, 19, 2030-2045.
141. Opar, A. New HIV drug classes on the horizon. Nat. Rev. Drug. Discov., 2007, 6, 258-259.
142. Summa, V.; Petrocchi, A.; Matassa, V.G.; Gardelli, C.; Muraglia, E.; Rowley, M.; Paz, O.G.; Laufer, R.; Monteagudo, E.; Pace, P. 4,5-Dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical species. J. Med. Chem., 2006, 49, 6646-6649.
143. Cohen, J. Novel attacks on HIV move closer to reality. Science, 2006, 311, 943-945.
144. de Melo, E.B.; Ferreira, M.M.C. Multivariate QSAR study of 4,5-dihydroxypyrimidine carboxamides as HIV-1 integrase inhibitors. Eur. J. Med. Chem., 2009, 44, 3577-3583.
145. de Melo, E.B.; Ferreira, M.M.C. Nonequivalent effects of diverse LogP algorithms in three QSAR studies. QSAR Comb. Sci., 2009, 28, 1156-1165.
146. Neamati, N.; Mazumder, A.; Sunder, S.; Owen, J.M.; Schultz, R.J.; Pommier, Y. 2-Mercaptobenzenesulfonamides as novel class of human immunodeficiency type 1 (HIV-1) integrase and HIV-1 replication. Antimicrob. Agents Chemother., 1997, 8, 485-495.
147. Kuo, C.-L.; Assefa, H.; Kamath, S.; Brzozowski, Z.; Slawinski, J.; Saczewski, F.; Buolamwini, J.K.; Neamati, N. Application of CoMFA and CoMSIA 3D-QSAR and docking studies in optimization of mercaptobenzenesulfonamides as HIV-1 integrase inhibitors. J. Med. Chem., 2004, 47, 385-399.
148. Gupta, P.; Roy, N.; Garg, P. Docking-based 3D-QSAR study of HIV-1 integrase inhibitors. Eur. J. Med. Chem., 2009, 44, 4276-4287.
149. Choe, H.; Farzan, M.; Sun, Y.; Sullivan, N.; Rollins, B.; Ponath, P.D.; Wu, L.; Mackay, C.R.; LaRosa, G.; Newman, W.; Gerard, N.; Gerard, C.; Sodroski, J. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell, 1996, 85, 1135-1148.
150. Dalgleish, A.G.; Beverley, P.C.L.; Clapham, P.R.; Crawford, D.H.; Greaves, M.F.; Weiss, R.A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature, 1984, 312, 763-767.
151. Kuhmann, S.E.; Hartley, O. Targeting chemokine receptors in HIV: A status report. Annu. Rev. Pharmacol. Toxicol., 2008, 48, 425-461.
152. Tsibris, A.M.; Kuritzkes, D.R. Chemokine antagonists as therapeutics: Focus on HIV-1. Annu. Rev. Med., 2007, 58, 445-459.
153. Kilby, J.M.; Eron, J.J. Novel therapies based on mechanisms of HIV-1 cell entry. N. Engl. J. Med., 2003, 348, 2228-2238.
154. Olson, W C.; Rabut, G.E.E.; Nagashima, K.A.; Tran, D.N.H.; Anselma, D.J.; Monard, S.P.; Segal, J.P.; Thompson, D.A.D.; Kajumo, F.; Guo, Y.; Moore, J.P.; Maddon, P.J.; Dragic, T. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J. Virol., 1999, 73, 4145-4155.
155. + T cells. Science, 1995, 270, 1811-1815.
156. Simmons, G.; Clapham, P.R.; Picard, L.; Offord, R.E.; Rosenkilde, M.M.; Schwartz, T.W.; Buser, R.; Wells, T.N.C.; Proudfoot, A.E.I. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science, 1997, 276, 276-279.
157. Heveker, N.; Montes, M.; Germeroth, L.; Amara, A.; Trautmann, A.; Alizon, M.; Schneider-Mergener, J. Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides. J. Curr. Biol., 1998, 8, 369-376.
158. Dorr, P.; Westby, M.; Dobbs, S.; Griffin, P.; Irvine, B.; Macartney, M.; Mori, J.; Rickett, G.; Smith-Burchnell, C.; Napier, C.; Webster, R.; Armour, D.; Price, D.; Stammen, B.; Wood, A.; Perros, M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother., 2005, 49, 4721-4732.
159. Gilliam, B.L.; Riedel, D.J.; Redfield, R.R. Clinical use of CCR5 inhibitors in HIV and beyond. J. Trans. Med., 2010, 9(Suppl 1), S9.
160. Song, M.; Breneman, C.M.; Sukumar, N. Three-dimensional quantitative structure-activity relationship analyses of piperidinebased CCR5 receptor antagonists. Bioorg. Med. Chem., 2004, 12, 489-499.
161. Leonard, J.T.; Roy, K. QSAR analyses of 3-(4-Benzylpiperidin-1-yl)-N-phenylpropylamine derivatives as potent CCR5 antagonists. J. Chem. Inf. Model., 2005, 45, 1352-1368.
162. Leonard, J.T.; Roy, K. Classical QSAR modeling of CCR5 receptor binding affinity of substituted benzylpyrazoles. QSAR Comb. Sci., 2004, 23, 387-397.
163. Teixeira, C.; Barbault, F.; Rebehmed, J.; Liu, K.; Xie, L.; Lu, H.; Jiang, S.; Fana, B.; Maurela, F. Molecular modeling studies of Nsubstituted pyrrole derivatives-Potential HIV-1 gp41 inhibitors. Bioorg. Med. Chem., 2008, 16, 3039-3048.
164. Teixeira, C.; Serradji, N.; Maurel, F.; Barbault, F. Docking and 3DQSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors. Eur. J. Med. Chem., 2009, 44, 3524-3532.
165. Pirhadi, S.; Ghasemi, J.B.; 3D-QSAR analysis of human immunodeficiency virus entry-1 inhibitors by CoMFA and CoMSIA. Eur. J. Med. Chem., 2010, 45, 4897-4903.
166. Afantitis, A.; Melagraki, G.; Sarimveis, H.; Igglessi-Markopoulou, O.; Kollias, G. A novel QSAR model for predicting the inhibition of CXCR3 receptor by 4-N-aryl-[1,4] diazepane ureas. Eur. J. Med. Chem., 2009, 44, 877-884.
167. Afantitis, A.; Melagraki, G.; Sarimveis, H.; Igglessi-Markopoulou, O.; Kollias, G. A combined LS-SVM & MLR QSAR workflow for predicting the inhibition of CXCR3 receptor by quinazolinone analogs. Mol. Divers., 2010, 14, 225-235.
168. Fogolari, F.; Brigo, A.; Molinari, H. The Poisson-Boltzmann equation for biomolecular electrostatics: A tool for structural biology. J. Mol. Recognit., 2002, 15, 377-392.
169. Simonson, T. Macromolecular electrostatics: Continuum models and their growing pains. Curr. Opin. Struct. Biol., 2001, 11, 243-252.
170. Sharp, K.A. Incorporating solvent and ion screening into molecular dynamics using the finite-difference Poisson-Boltzmann method. J. Comput. Chem., 1991, 12, 454-468.
171. Lazaridis, T.; Karplus, M. Effective energy function for proteins in solution. Proteins, 1999, 35, 133-152.
172. Felts, A.K.; Labarge, K.; Bauman, J.D.; Patel, D.V.; Himmel, D.M.; Arnold, E.; Parniak, M.A.; Levy, R.M. Identification of alternative binding sites for inhibitors of HIV-1 ribonuclease Hthrough comparative analysis of virtual enrichment studies. J. Chem. Inf. Model., 2011, 51, 1986-1998.
173. Da, L.T.; Quan, J.M.; Wu, Y.D. Understanding the binding mode and function of BMS-488043 against HIV-1 viral entry. Proteins, 2011, 79, 1810-1819.
174. Metz, M.; Bourque, E.; Labrecque, J.; Danthi, S.J.; Langille, J.; Harwig, C.; Yang, W.; Darkes, M.C.; Lau, G.; Santucci, Z.; Bridger, G.J.; Schols, D.; Fricker, S.P.; Skerlj, R.T. Prospective CCR5 small molecule antagonist compound design using a combined mutagenesis/modeling approach. J. Am. Chem. Soc., 2011, 133, 16477-16485.
175. Shrivastava, I.; LaLonde, J.M. Enhanced dynamics of HIV gp120 glycoprotein by small molecule binding. Biochemistry, 2011, 50, 4173-4178.
176. Mori, M.; Manetti, F.; Botta, M. Predicting the binding mode of known NCp7 inhibitors to facilitate the design of novel modulators. J. Chem. Inf. Model., 2011, 51, 446-454.
177. Bacchi, A.; Carcelli, M.; Compari, C.; Fisicaro, E.; Pala, N.; Rispoli, G.; Rogolino, D.; Sanchez, T.W.; Sechi, M.; Neamati, N. HIV-1 IN strand transfer chelating inhibitors: A focus on metal binding. Mol. Pharm., 2011, 8, 507-519.
178. Huang, M.; Grant, G.H.; Richards, W.G. Binding modes of diketoacid inhibitors of HIV-1 integrase: A comparative molecular dynamics simulation study. J. Mol. Graph. Model., 2011, 29, 956-964.
179. Hu, G.D.; Zhu, T.; Zhang, S.L.; Wang, D.; Zhang, Q.G. Some insights into mechanism for binding and drug resistance of wild type and I50V V82A and I84V mutations in HIV-1 protease with GRL-98065 inhibitor from molecular dynamic simulations. Eur. J. Med. Chem., 2010, 45, 227-235.
180. Johnson, B.C.; Metifiot, M.; Pommier, Y.; Hughes, S.H. Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity. Antimicrob. Agents Chemother., 2011, 56, 411-419.
181. Hartonoa, Y.D.; Lee, A.N.; Lee-Huang, S.; Zhang, D. Computational study of bindings of HL9, a nonapeptide fragment of human lysozyme, to HIV-1 fusion protein gp41. Bioorg. Med. Chem. Lett., 2011, 21, 1607-1611.
182. Venken, T.; Krnavek, D.; Munch, J.; Kirchhoff, F.; Henklein, P.; De Maeyer, M.; Voet, A. An optimized MM/PBSA virtual screening approach applied to an HIV-1 gp41 fusion peptide inhibitor. Proteins, 2011, 79, 3221-3235.
183. Tzoupis, H.; Leonis, G.; Durdagi, S.; Mouchlis, V.; Mavromoustakos, T.; Papadopoulos, M.G. Binding of novel fullerene inhibitors to HIV-1 protease: Insight through molecular dynamics and molecular mechanics Poisson-Boltzmann surface area calculations. J. Comput.-Aided Mol. Des., 2011, 25, 959-997.
184. Ucisik, M.N.; Dashti, D.S.; Faver, J.C.; Merz Jr., K.M. Pairwise additivity of energy components in protein-ligand binding: The HIV II protease-indinavir case. J. Chem. Phys., 2011, 135, 085101-085113.
185. Deng, J.; Lee, K.W.; Sanchez, T.; Cui, M.; Neamati, N.; Briggs, J.M. Dynamic receptor-based pharmacophore model development and its application in designing novel HIV-1 integrase inhibitors. J. Med. Chem., 2005, 48, 1496-505.
186. Carlson, H.A.; Masukawa, K.M.; Rubins, K.; Bushman, F.D.; Jorgensen, W.L.; Lins, R.D.; Briggs, J.M.; McCammon, J.A. Developing a dynamic pharmacophore model for HIV-1 integrase. J. Med. Chem., 2000, 43, 2100-2114.
187. Deng, J.; Sanchez, T.; Neamati, N.; Briggs, J.M. Dynamic pharmacophore model optimization: identification of novel HIV-1 integrase inhibitors. J. Med. Chem., 2006, 49, 1684-1692.
188. B-Rao, C.; Subramanian, J.; Sharma, S.D. Managing protein flexibility in docking and its applications. Drug Discov. Today, 2009, 14, 394-400.
189. Huang, S.-Y.; Zo, X. Ensemble docking of multiple protein structures: Considering protein structural variations in molecular docking. Proteins, 2007, 66, 399-421.
190. Totrov, M.; Abagyan, R. Flexible ligand docking to multiple receptor conformations: A practical alternative. Curr. Opin. Struct. Biol., 2008, 18, 178-84.
191. Roberts, B.C.; Mancera, R.L. Ligand-protein docking with water molecules. J. Chem. Inf. Model., 2008, 48, 397-408.
192. Rao, B.G.; Tilton, R.F.; Singh, U.C. Free energy perturbation studies on inhibitor binding to HIV-1 proteinase. J. Am. Chem. Soc., 1992, 114, 4447-4452.
193. McCarrick, M.A.; Kollman, P.A. Predicting relative binding affinities of non-peptide HIV protease inhibitors with free energy perturbation calculation. J. Comput.-Aided Mol. Des., 1999, 13, 109-121.
194. Eriksson, M.A.L.; Pitera, J.; Kollman, P.A. Prediction of the binding free energies of new TIBO-like HIV-1 reverse transcriptase inhibitors using a combination of PROFEC, PB/SA, CMC/MD, and free energy calculations. J. Med. Chem., 1999, 42, 868-881.
195. Jorgensen, W.L.; Bollini, M.; Thakur, V.V.; Domaoal, R.A.; Spasov, K.A.; Anderson, K.S. Efficient discovery of potent Anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase. J. Am. Chem. Soc., 2011, 133, 15686-15696.
196. Bollini, M.; Domaoal, R.A.; Thakur, V.V.; Gallardo-Macias, R.; Spasov, K.A.; Anderson, K.S.; Jorgensen, W.L. Computationallyguided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents. J. Med. Chem., 2011, 54, 8582-8591.
197. Sadiq, S.K.; Wright, D.W.; Kenway, O.A.; Coveney, P.V. Accurate ensemble molecular dynamics binding free energy ranking of multidrug-resistant HIV-1 proteases. J. Chem. Inf. Model., 2010, 50, 890-905.
198. Srivani, P.; Usharani, D.; Jemmis, E.D.; Sastry, G.N. Subtype selectivity in phosphodiesterase 4 (PDE4): A bottleneck in rational drug design. Curr. Pharma. Design., 2008, 14, 3854-3872.
199. Murthy, J.N.; Nagaraju, M.; Sastry, G.M.; Rao, A.R.; Sastry, G.N. Active site acidic residues and structural analysis of modelled human aromatase: A potential drug target for breast cancer. J. Comput. Aided. Mol. Des., 2005, 19, 857-870.
200. Musmuca, I.; Caroli, A.; Mai, A.; Kaushik-Basu, N.; Arora, P.; Ragno, R. Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors. J. Chem. Inf. Model., 2010, 50, 662-676.
201. Srivani, P.; Srinivas, E.; Raghu, R.; Sastry, G.N. Molecular modeling studies of pyridopurinone derivatives-Potential phosphodiesterase 5 inhibitors. J. Mol. Graph. Model., 2007, 26, 378-390.
202. Patel, P.D.; Patel, M.R.; Kaushik-Basu, N.; Talele, T.T. 3D QSAR and molecular docking studies of benzimidazole derivatives as hepatitis C virus NS5B polymerase inhibitors. J. Chem. Inf. Model., 2008, 48, 42-55.
203. World Health Organization 2009 (www.who.int).
204. Grant, R.M.; Lama, J.R.; Anderson, P.L.; McMahan, V.; Liu, AY.; Vargas, L.; Goicochea, P.; Casapía, M.; Guanira-Carranza, J.V.; Ramirez-Cardich, M.E.; Montoya-Herrera, O.; Fernández, T.; Veloso, V.G.; Buchbinder, S.P.; Chariyalertsak, S.; Schechter, M.; Bekker, L.G.; Mayer, K.H.; Kallás, E.G.; Amico, K.R.; Mulligan, K.; Bushman, L.R.; Hance, R.J.; Ganoza, C.; Defechereux, P.; Postle, B.; Wang, F.; McConnell, J.J.; Zheng, J.H.; Lee, J.; Rooney, J.F.; Jaffe, H.S.; Martinez, A.I.; Burns, D.N.; Glidden, D.V. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med., 2010, 363, 2587-2599.
205. Watts, J.M.; Dang, K.K.; Gorelick, R.J.; Leonard, C.W.; Bess, J.W.; Swanstrom, R.; Burch, C.L.; Weeks, K.M. Architecture and secondary structure of an entire HIV-1 RNA genome. Nature, 2009, 460, 711-716.
206. Portsmouth, S.D.; Scott, C.J. The renaissance of fixed dose combinations: Combivir. Ther. Clin. Risk. Manag., 2007, 3, 579-583.
207. FDA notifications: FDA Approves first oral fluid based rapid HIV test, March 26, 2004, (http://www.fda.gov/ForConsumers/ByAudi ence/ForPatientAdvocates/HIVandAIDSActivities/ucm125034.htm).
208. FDA notifications. FDA approves Fuzeon, the first fusion inhibitor. AIDS Alert., 2003, 18, 78-79.
209. Lalezari, J.P.; Henry, K.; O'Hearn, M.; Montaner, J.S.G.; Piliero, P.J.; Trottier, B.; Walmsley, S.; Cohen, C.; Kuritzkes, D.R.; Eron, J.J.; Chuang, J.; DeMasi, R.; Donatacci, L.; Drobnes, C.; Delehanty, J.; Salgo, M. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med., 2003, 348, 2175-2185.
210. Gallo, R.C. Historical essay. The early years of HIV/AIDS. Science, 2002, 298, 1728-1730.
211. WHO (1999) The World Health Report (www.who.int/whr/1999/en/index.html).
212. Joseph, J.; Etcheverry, F.; Alcami, J.; GateII, J.M.A. Safe, effective and affordable HIV vaccine: An urgent global need. AIDS Rev., 2005, 7, 131-138.
213. Wlodawer, A. Rational approach to aids drug design through structural biology. Annu. Rev. Med., 2002, 53, 595-614.
214. James, J.S. Saquinavir (Invirase): First protease inhibitor approved. AIDS Treat. News, 1995, 237, 1-2.
215. Meng, T.C.; Fischl, M.A.; Boota, A.M.; Spector, S.A.; Bennett, D.; Bassiakos, Y.; Lai, S.; Wright, B.; Richman, D.D. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. Annal. Int. Med., 1992, 116, 113-120.
216. FDA authorized pre-approval distribution of dideoxycytidine (ddC) under a treatment IND protocol for the treatment of patients with AIDS who cannot be maintained on AZT, 1991. (http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvoca tes/HIVandAIDSActivities/ucm151078.htm).
217. Baba, M.; Tanaka, H.; De Clercq, E.; Pauwels, R.; Balzarini, J.; Schols, D.; Nakashima, H.; Perno, C.-F.; Walker, R.T.; Miyasaka, T. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem. Biophys. Res. Commun., 1989, 165, 1375-1381.
218. Cimons, M. U.S. Approves Sale of AZT to AIDS Patients. Los Angeles Times, 21 March 1987, pp-1.
219. Kallings, L.O. The first postmodern pandemic: 25 years of HIV/AIDS. J. Int. Med., 2008, 263, 218-243.
220. Coffin, J.; Haase, A.; Levy, J.A.; Montagnier, L.; Oroszlan, S.; Teich, N.; Temin, H.; Toyoshima, K.; Varmus, H.; Vogt, P.; Weiss, R.A. What to call the AIDS virus? Nature, 1986, 321, 10.
221. Michalski, F.J. The diagnosis of human immunodeficiency virus infection: Progress in less than five years. Yale J. Biol. Med., 1989, 62, 93-102.
222. Popovic, M.; Sarngadharan, M.G.; Read, E.; Gallo, R.C. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science, 1984, 224, 497-500.
223. Mitsuya, H.; Popovic, M.; Yarchoan, R.; Matsushita, S.; Gallo, R.C.; Broder, S. Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science, 1984, 226, 172-174.
224. Broder, S.; Yarchoan, R.; Collins, J.M.; Lane, H.C.; Markham, P.D.; Klecker, R.W.; Redfield, R.R.; Hoth, D.F.; Mitsuya, H.; Gelmann, E.; Resnick, L.; Myers, C.; Fauci, A.S. Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: Clinical pharmacology and suppression of virus replication in vivo. Lancet, 1985, 2, 627-630.
225. Barré-Sinoussi, F.; Chermann, J.C.; Rey, F.; Nugeyre, M.T.; Chamaret, S.; Gruest, J.; Dauguet, C. Axler-Blin, C.; Vézinet-Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Isolation of a Tlymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science, 1983, 220, 868-871.
226. Gottlieb, M.S.; Schroff, R.; Schanker, H.M.; Weisman, J.D.; Fan, P.T.; Wolf, R.A.; Saxon, A. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency. N. Engl. J. Med., 1981, 305, 1425-1431.
227. Das, K.; Bauman, J.D.; Clark Jr., A.D.; Frenkel, Y.V.; Lewi, P.J.; Shatkin, A.J.; Hughes, S.H.; Arnold, E. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations. Proc. Natl. Acad. Sci. USA, 2008, 105, 1466-1471.
228. Hidaka, K.; Kimura, T.; Abdel-Rahman, H.M.; Nguyen, J.T.; McDaniel, K.F.; Kohlbrenner, W.E.; Molla, A.; Adachi, M.; Tamada, T.; Kuroki, R.; Katsuki, N.; Tanaka, Y.; Matsumoto, H.; Wang, J.; Hayashi, Y.; Kempf, D.J.; Kiso, Y. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket. J. Med. Chem., 2009, 52, 7604-7617.
229. Wielens, J.; Headey, S.J.; Deadman, J.J.; Rhodes, D.I.; Parker, M.W.; Chalmers, D.K.; Scanlon, M.J. Fragment-based design of ligands targeting a novel site on the integrase enzyme of human immunodeficiency virus. Chem. Med. Chem., 2011, 6, 258-261.
230. Stierand, K.; Rarey, M. Drawing the PDB: Protein-ligand complexes in two dimensions. Med. Chem. Lett., 2010, 1, 540-545.
231. Stierand, K.; Rarey, M. From modeling to medicinal chemistry: Automatic generation of two-dimensional complex diagrams. Chem. Med. Chem., 2007, 2, 853-860.
232. Fricker, P.; Gastreich, M.; Rarey, M. Automated generation of structural molecular formulas under constraints. J. Chem. Inf. Comput. Sci., 2004, 44, 1065-1078.
233. Stierand, K.; Maaß, P.; Rarey, M. Molecular complexes at a glance: Automated generation of two-dimensional complex diagrams. Bioinformatics, 2006, 22, 1710-1716.